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protecting the institution than protecting the
experimental subject. We argued that perhaps these
individuals would be better off if they got a description
of the general level of risk, but detailed risk
possibilities, or even very slight risks, ought to be
reserved for those who request them.And if the detailed
information is given, it ought to be accompanied by a
discussion of placebo effects – why they occur, and how
to guard against them.
Critics were quick to jump on these ideas, arguing that
the “right to full information on matters which may
affect our minds and bodies prevails” (3). They accused
us of displaying a distressing failure to make a
distinction between rights and benefits. We were
astonished that our critics would so readily construe a
statement intended to be made in favor of human rights
as an attack upon such rights. Of course, people have
the right to determine what is done to their minds and
bodies, but this must extend to symptoms and illness
actually caused by poorly executed disclosure. We
question, informed by our knowledge of the power of
placebos, whether the current legalistic ritual associated
with informed consent is the best way to ensure that this
human right is protected. We only ask that those whose
task it is to formulate informed consent rituals pay some
attention to the harm that may be caused by the ritual
itself. One harm is the planting of suggested symptoms,
some of which can be rather unpleasant, such as anxiety,
or downright distressing, such as severe physiological
reactions. Would the critics actually endorse the idea
that those involved in formulating these rituals have a
right to harm people? Patients and subjects might be far
less damaged by smaller amounts of balanced
information than by mammoth descriptions of remote
possibilities. We always advocated supplying the
information to those who choose to know all, but to
include in the presentation of the “all” a discussion of
placebo effects and their potential for adverse reactions.
At the time we were immersed in this issue, we
Informed consent is supposed to be a good thing, isn’t
it? Motherhood, apple pie, and informed consent.After
all, we don’t want the return of the bad old days when
unwitting human guinea pigs were experimented upon
without knowing what they were getting into. But there
is another side to informed consent; in fact, there are
perils to informed consent that ought to make the
medical establishment think harder before continuing to
uncritically accept it as a universal constant.
Some time ago, we wrote an editorial in Science
entitled “Informed consent may be hazardous to your
health” (1). There we pointed to the rather suggestible
nature of the human mind. We know that plying people
with certain kinds of information can make them
believe that they experienced things that never
happened. Studies on the malleability of human
memory have shown that people can be led to believe
that they saw stop signs instead of yield signs, that they
got sick eating particular foods as children, and that
they even had experiences that are highly implausible
such as witnessing people being demonically possessed
or being accosted by the Pluto character on a trip to a
Disney resort (2).
Not only can people be led to believe that they
experienced events that did not occur, but they can also
be led to experience feelings and symptoms that they
would not otherwise feel. That’s what placebos are all
about. When a physician tells a patient or experimental
subject that the drug being taken might cause nausea or
dizziness, how many people develop the symptoms who
wouldn’t do so from the drug or the medical procedure
alone? We argued that simple inspection of informed
consent documents reveals a purpose more directed at
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conducted an unpublished pilot study with patients at
Stanford University Medical School who had been
diagnosed with scleroderma and were enrolled in an
experiment testing the efficacy of a particular drug
cocktail (propanolol and alpha-methyldopa). The
known side effects of the drugs did include upset
stomach, tearfulness, dizziness, and headache. Before
beginning the clinical trial involving the drug or
placebo, patients received either a standard informed
consent message or a “special message.” Both
messages informed them of possible side effects of the
drug, and listed the known side effects, plus some
implausible made-up ones that had not been associated
with the drug (e.g., ringing in ears, burning sensation in
feet).
Some of our subjects received a “special message” as
part of their “informed consent.” It read as follows:
“You should keep in mind one important point about
these possible side effects. Research has shown that
simply mentioning possible annoying symptoms causes
some people to experience these symptoms – even
when no drug is taken at all. This happens because
mention of the symptoms causes some people to expect
that they will experience them, and a person’s
expectations can then lead to the actual experience.
Very few people will actually have these problems and
you can help yourself guard against these sorts of
discomfort by keeping yourself optimistic and stopping
yourself from expecting that side effects are going to
happen to you.”
Our pilot study revealed, not surprisingly, that
subjects experienced side effects, some of which were
physiologically unlikely. The suggestion in the
informed consent led even those given a placebo to this
unpleasant fate. A special message that explained the
powerful role that expectations can have in producing
unlikely symptoms reduced the reported side effects,
and also decreased somewhat the use of medications to
treat those unlikely symptoms. Our hope is that future
researchers will do a full scale study that tests the
impact of variations in informed consent rituals. While
our special message may not be the best message to
accomplish these hoped-for benefits, and we did not
study whether it will work with different kinds of drugs
or patients, our preliminary result should pique the
interest of future researchers in considering both the
positive and negative impacts of information that they
ply their subjects and patients with. One size is not
likely to fit all. Flexibility in informed consent
protocols might convey to patients and subjects their
right to as little harm as possible.
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